로딩 중…
지수 로딩 중…
Amicogen, Inc.
092040· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,513+15.41%
2026-06-19
Price Chart
Amicogen, Inc.-58.15%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 106.90B KRW |
| Revenue | 43.44B KRW |
| Net Income | -5.28B KRW |
| Total Assets | 213.68B KRW |
| Net Assets | 133.35B KRW |
| Employees | 223 |
| Value | |
| P/B | 0.80x |
| P/S | 2.46x |
| FCF Yield | -26.32% |
| Profitability | |
| ROE | -3.96% |
| ROA | -2.47% |
| Op. Margin | -36.79% |
| Revenue Growth | 13.49% |
| Financial Health | |
| Debt Ratio | 160.24% |
| Total Debt | 61.43B KRW |
| FCF | -28.13B KRW |
| Cash | 6.74B KRW |
| Current Ratio | 1.07x |
| Dividend | |
| Div. Growth | 0.00% |
| Performance | |
| 1Y Return | -58.15% |
| 1M Return | -19.52% |
| From 52W High | -65.92% |
| 1Y MDD | -74.95% |
| Trading | |
| Volume | 6,745,073 shares |
| Foreign Own. | 3.67% |
| Per Share | |
| EPS | -79 KRW |
| BPS | 1,879 KRW |
Company Info
Amicogen, established in 2000, is an industrial bio-specialized company that develops and produces special enzymes for pharmaceuticals, biomaterials for pharmaceuticals, and enzyme-based new biomaterials using genetic evolution technology. The company supplies CX enzyme for 7-ACA production to the global market, pursues localization of purification resins and media for antibody biopharmaceuticals, and expands its health functional food business. By securing production technology and promoting its next-generation antibiotic enzyme CDMO business, Amicogen aims to expand its global market through large-scale commercialization of biopharmaceutical materials. Amicogen is headquartered in Jinju-si, Gyeongsangnam-do.